Effect of esmolol- lignocaine infusion in improving cardiac functions and decreasing irregular heart beat post operatively when given during cardiac bypass surgeries.
Phase 2
Completed
- Conditions
- Health Condition 1: I00-I99- Diseases of the circulatory systemHealth Condition 2: null- patients undergoing cardiac surgeries under cardiopulmonary bypass
- Registration Number
- CTRI/2018/01/011555
- Lead Sponsor
- CTVS ICU Advanced Cardiac centre PGIMER
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 98
Inclusion Criteria
patients with cardiac disease undergoing cardiac surgery under cardio-pulmonary bypass with ejection fraction of <50% for Coronary artery bypass graft surgeries And <60% for Aortic regurgitation and Mitral regurgitation valve repair surgeries .
Exclusion Criteria
Patients not willing for the study,with asthma, existing atrial flutter or fibrillation, allergy to esmolol or lignocaine, hepatic or renal dysfunction.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To compare the incidence of arrhythmias after CPB either by using HOLTERS monitor or saved ECG record in the ICU monitor during first 24 hours in patients receiving esmolol-lignocaine infusion on CPB with control group receiving placebo infusion.Timepoint: first 24 hours post CPB.
- Secondary Outcome Measures
Name Time Method To compare pain score,analgesia requirement, inotropic requirement and mechanical ventilation duration post operatively after CPB separation for first 24 hours.Timepoint: first 24 hours post CPB